<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Reactive infectious mucocutaneous eruption (RIME)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Reactive infectious mucocutaneous eruption (RIME)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Reactive infectious mucocutaneous eruption (RIME)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erin Mathes, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicole W Kittler, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H55047595"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Reactive infectious mucocutaneous eruption (RIME) refers to a severe mucocutaneous adverse reaction that occurs predominantly in children and adolescents following a bacterial or viral respiratory infection (most commonly <em>Mycoplasma pneumoniae</em> infection) [<a href="#rid1">1-3</a>]. RIME is characterized by prominent mucositis, usually with sparse or even absent cutaneous involvement. Compared with the Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) spectrum, RIME has a distinct pathophysiology, a milder course, and a generally good prognosis.</p><p>This topic will discuss the pathogenesis, clinical manifestations, diagnosis, and treatment of RIME. SJS/TEN and erythema multiforme (EM) are discussed separately. <em>M. pneumoniae</em> infection in children and adults is also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2092.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5559.html" rel="external">"Erythema multiforme: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5561.html" rel="external">"Erythema multiforme: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6070.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6989.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in adults"</a>.)</p><p></p><p class="headingAnchor" id="H3624327753"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The term "<em>Mycoplasma pneumoniae</em>-induced rash and mucositis" (MIRM) was coined in 2015 to distinguish the mucocutaneous disease associated with <em>Mycoplasma</em> from the Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) spectrum and erythema multiforme (EM) [<a href="#rid4">4</a>]. Prior to that distinction, cases of <em>Mycoplasma</em>-induced mucocutaneous disease were referred to as SJS [<a href="#rid5">5-7</a>], atypical SJS [<a href="#rid8">8</a>], Fuchs syndrome [<a href="#rid9">9,10</a>], TEN [<a href="#rid11">11</a>], EM [<a href="#rid12">12</a>], and <em>Mycoplasma pneumoniae</em>-associated mucositis (MPAM) [<a href="#rid13">13-15</a>].</p><p>Based on the subsequent observation that other bacterial and viral respiratory infections can cause a mucocutaneous reaction in children, it has been proposed that MIRM should be included in a broader category called "reactive infectious mucocutaneous eruption" (RIME). RIME describes mucocutaneous eruptions resulting from a variety of infectious triggers and differentiates infectious triggers, which are far more likely in children and adolescents, from drug triggers [<a href="#rid16">16-19</a>].</p><p>The term RIME will be the preferred term used in this topic.</p><p class="headingAnchor" id="H2934766669"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>RIME primarily affects children and young patients (mean age 12 years), more commonly males, with rare adult cases reported [<a href="#rid4">4,20-24</a>]. RIME most often occurs during winter [<a href="#rid25">25</a>]. Community outbreaks of RIME associated with <em>M. pneumoniae</em> infection<em> </em>have been described [<a href="#rid26">26,27</a>].</p><p class="headingAnchor" id="H3818043939"><span class="h1">ETIOLOGY AND PATHOGENESIS</span><span class="headingEndMark"> — </span>While several respiratory infections have been reported to cause RIME, <em>M. pneumoniae</em>, a leading cause of community-acquired pneumonia, is the most common trigger [<a href="#rid3">3,28,29</a>]. Children serve as the primary reservoir for <em>M. pneumoniae</em>, and transmission occurs via respiratory droplets through close personal contact (especially within households) [<a href="#rid26">26,28,29</a>]. <em>M. pneumoniae </em>infections are characterized by a long incubation period (up to four weeks) and asymptomatic carriage for weeks following infections [<a href="#rid26">26</a>]. <em>M. pneumoniae</em> is the most frequent etiologic agent of RIME in children. However, mucocutaneous eruptions indistinguishable from those described with <em>M. pneumoniae</em> have been reported with <em>Chlamydia pneumoniae</em>, human metapneumovirus, parainfluenza virus type 2, influenza B virus, rhinovirus, enteroviruses (including coxsackievirus), adenovirus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [<a href="#rid16">16,18,19,30-36</a>].</p><p>Reports describing recurrent RIME by <em>M. pneumoniae</em> and other infections, familial cases, and recurrence in multiple individuals within families suggest that there may be genetic determinants of susceptibility, although none have been identified [<a href="#rid4">4,34,37-41</a>].</p><p>The exact pathogenesis of RIME is unknown. Two primary mechanisms have been proposed:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indirect</strong> – In this mechanism, which is the most commonly accepted, an immune response is triggered by a distant infection leading to tissue damage [<a href="#rid17">17,29</a>]. Polyclonal B cell proliferation and antibody production can lead to skin damage via immune complex deposition and complement activation. As an example, molecular mimicry between <em>M. pneumoniae </em>P1-adhesion molecules and keratinocyte antigens may contribute to this pathway [<a href="#rid42">42,43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Direct</strong> – Bacteria or other infectious agents present at mucocutaneous sites induce local release of inflammatory cytokines and tissue damage. This mechanism is supported by early studies reporting isolation of <em>M. pneumoniae </em>from skin blister fluid [<a href="#rid44">44-46</a>]. However, subsequent studies have not confirmed this finding [<a href="#rid25">25</a>]. Because <em>M. pneumoniae</em> cannot infect squamous cell epithelium, hematogenous spread from the respiratory tract to the skin would be required to cause direct infection [<a href="#rid47">47</a>]. The variable extent of mucocutaneous involvement, frequent involvement of distant sites, and expanding range of associated infections all make this mechanism unlikely.</p><p></p><p class="headingAnchor" id="H4200489136"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>RIME is characterized by severe mucositis and variable, but generally sparse, cutaneous lesions. Most patients experience a prodrome of cough, malaise, and fever for approximately one week prior to the onset of their mucocutaneous eruption [<a href="#rid4">4</a>]. Although predominantly described in children and adolescents, RIME can also occur in adults.</p><p class="headingAnchor" id="H3648606874"><span class="h2">Mucosal and cutaneous findings</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucosal findings</strong> – On average, patients have two to three mucosal sites affected [<a href="#rid4">4,20</a>]. Oral involvement is nearly universal, with hemorrhagic crusting of the lips and erosions on the tongue and buccal mucosa  (<a class="graphic graphic_picture graphicRef126080 graphicRef126081" href="/z/d/graphic/126080.html" rel="external">picture 1A-B</a>) [<a href="#rid4">4,20</a>]. Isolated oral erosions and ulcers can also occur [<a href="#rid4">4</a>]. The majority of patients have ocular involvement, most often characterized by a purulent bilateral conjunctivitis  (<a class="graphic graphic_picture graphicRef126082" href="/z/d/graphic/126082.html" rel="external">picture 2</a>). Photophobia and eyelid edema may also occur [<a href="#rid4">4,48</a>]. Urogenital lesions occur in approximately 60 percent of patients and can affect the vulva, vagina, any part of the penis (including the urethral meatus), and scrotum [<a href="#rid4">4</a>]. Nasal and anal mucosa may also be involved and should be evaluated [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous findings</strong> – The morphology of skin lesions of RIME varies, but vesiculobullous lesions are most common (occurring in nearly 80 percent of cases) [<a href="#rid4">4</a>]. Targetoid  (<a class="graphic graphic_picture graphicRef134312" href="/z/d/graphic/134312.html" rel="external">picture 3</a>), papular, morbilliform, and transient macular or serpiginous annular eruptions  (<a class="graphic graphic_picture graphicRef134313" href="/z/d/graphic/134313.html" rel="external">picture 4</a>) have all been described [<a href="#rid4">4,50</a>]. Lesions are usually sparsely scattered on the extremities and trunk, with occasional involvement of the face.</p><p></p><p class="headingAnchor" id="H1886145475"><span class="h2">Clinical variants</span><span class="headingEndMark"> — </span>Rarely, patients may present with clinical variants of RIME. These include the involvement of fewer than two mucosal surfaces and extensive cutaneous involvement [<a href="#rid4">4</a>]. In addition to the typical cutaneous lesions of RIME, some patients may develop a subcorneal pustular eruption [<a href="#rid51">51</a>]. The classic, acral (palmoplantar), target lesions of erythema multiforme (EM) and the extensive epidermal detachment of toxic epidermal necrolysis (TEN) are exceedingly rare in RIME and should prompt further evaluation for other causes, such as other infections or medications. Some patients may present with only mucosal involvement (RIME "sine rash").</p><p class="headingAnchor" id="H3763314697"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Patients with RIME often have elevated acute phase reactants, including C-reactive protein and erythrocyte sedimentation rate [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H1060372708"><span class="h2">Recurrent RIME</span><span class="headingEndMark"> — </span>Recurrence of RIME has been reported in 9 to 38 percent of patients in case series [<a href="#rid3">3,4,34,36,41</a>]. Most recurrent cases appear to be triggered by different viral or bacterial agents rather than re-exposure to the initial pathogen, although a triggering agent cannot be found in many cases [<a href="#rid34">34,41</a>].</p><p class="headingAnchor" id="H3094655403"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>There are no histopathologic features that are pathognomonic of RIME. RIME shares features of both erythema multiforme (EM) major and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), including apoptotic keratinocytes and a sparse, perivascular, dermal infiltrate [<a href="#rid52">52,53</a>]. In one study, biopsies from cases initially diagnosed as <em>M. pneumoniae</em>-induced EM that were also consistent with a diagnosis of RIME were characterized by full-thickness epidermal necrosis and detachment, resembling SJS/TEN more than EM [<a href="#rid25">25</a>]. These findings indicate that the histologic differentiation of RIME, EM, and SJS/TEN is difficult or impossible. Investigators have been unable to identify <em>M. pneumoniae</em> in lesional skin by polymerase chain reaction (PCR) [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H3567431412"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>RIME should be suspected in a child or young patient presenting with a mucosal or mucocutaneous eruption and a history of prodromal symptoms, including cough, malaise, and fever, preceding the eruption by approximately one week [<a href="#rid4">4</a>]. Laboratory evidence of <em>M. pneumoniae</em> or <em>C. pneumoniae</em> infection supports the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/6070.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in children"</a> and  <a class="medical medical_review" href="/z/d/html/5957.html" rel="external">"Pneumonia caused by <i>Chlamydia pneumoniae</i> in children"</a>.)</p><p class="headingAnchor" id="H2018658744"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>Proposed diagnostic criteria for RIME include [<a href="#rid1">1,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mucocutaneous eruption involving one or more sites with &lt;10 percent body surface area involvement</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of a few vesiculobullous lesions or scattered, atypical, targetoid lesions on skin</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Noncontributory medication history</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of prodromal symptoms (eg, cough, fever, malaise) in the previous 7 to 10 days</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical, radiographic, or laboratory evidence of an infectious trigger (most commonly <em>M. pneumoniae</em>, respiratory viruses, or <em>C. pneumoniae</em>) (see <a class="local">'Imaging and laboratory tests'</a> below)</p><p></p><p>Other authors have suggested adding young age to the diagnostic criteria, as RIME is very rare in adults [<a href="#rid49">49</a>].</p><p>The clinical diagnosis of atypical pneumonia is based on the presence of fever, cough, fatigue, and positive auscultatory findings. (See  <a class="medical medical_review" href="/z/d/html/6070.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in children", section on 'Pneumonia'</a>.)</p><p class="headingAnchor" id="H310530005"><span class="h2">Imaging and laboratory tests</span><span class="headingEndMark"> — </span>Radiologic and laboratory investigations to confirm the diagnosis of respiratory infection include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest radiograph</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tests for </strong><strong><em>M. pneumoniae</em></strong><strong> infection </strong>– Confirmatory laboratory tests for <em>M. pneumoniae</em> include polymerase chain reaction (PCR) of pharyngeal swab and measurement of serum-specific immunoglobulin G (IgG), immunoglobulin M (IgM), and immunoglobulin A (IgA) titers [<a href="#rid54">54</a>]. Although PCR is highly sensitive and specific, it can remain positive for up to four months after infection, making it difficult to distinguish acute from past infection. IgM titers start to increase approximately seven to nine days after infection, peak at three to six weeks, and persist for months. IgG titers begin to rise and peak approximately two weeks after IgM titers and persist for years. Thus, as both IgM and IgG may be normal in the acute phase, documentation of titer increase in paired sera is needed for accurate serologic diagnosis. (See  <a class="medical medical_review" href="/z/d/html/6070.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in children", section on 'Laboratory tests'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tests for </strong><strong><em>C. pneumoniae</em></strong><strong> infection</strong> – A PCR-based assay can be used for the confirmation of <em>C. pneumoniae</em> infection. The test can be performed on a variety of specimens, including nasopharyngeal swabs, sputum, and bronchoalveolar lavage fluid. (See  <a class="medical medical_review" href="/z/d/html/5957.html" rel="external">"Pneumonia caused by <i>Chlamydia pneumoniae</i> in children", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tests for respiratory virus infections</strong> – PCR respiratory panels that include multiple respiratory viruses in addition to <em>M. pneumoniae</em> and <em>C. pneumoniae</em> are also commercially available [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tests for SARS-CoV-2 infection</strong> – The diagnosis of coronavirus disease 2019 (COVID-19) is made by direct detection of SARS-CoV-2 ribonucleic acid (RNA) using real-time PCR or by detection of viral protein using an antigen test. A positive nucleic acid amplification test (NAAT) or antigen test is generally indicative of infection. (See  <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a>.)</p><p></p><p>There are rare reports of gastrointestinal pathogens causing RIME [<a href="#rid56">56</a>]. Additional testing, as indicated by a patient's history and clinical findings, may be needed.</p><p class="headingAnchor" id="H560522478"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>A mucosal or cutaneous biopsy is not routinely performed for the diagnosis of RIME. As discussed above, histopathologic examination cannot reliably distinguish among RIME, erythema multiforme (EM), or Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) (see <a class="local">'Pathology'</a> above). However, a skin biopsy including direct immunofluorescence should be performed if an autoimmune blistering disorder is being considered in the differential diagnosis. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H936874589"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of RIME includes other disorders characterized by mucositis and rash, including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythema multiforme (EM)</strong> <strong>major</strong> – EM is caused by herpes simplex virus (HSV) infection in most cases and rarely by other viral or bacterial infections or drugs. It can be clinically distinguished from RIME by the lesional morphology and distribution. EM presents with acute onset of acrally distributed, classic, target lesions, which can become bullous centrally  (<a class="graphic graphic_picture graphicRef79955" href="/z/d/graphic/79955.html" rel="external">picture 5</a>). In EM minor, the lips can be involved, but multiple mucosal surfaces are not involved  (<a class="graphic graphic_picture graphicRef62370" href="/z/d/graphic/62370.html" rel="external">picture 6</a>). In EM major, severe mucosal lesions occur in association with cutaneous lesions but rarely involve more than one site  (<a class="graphic graphic_picture graphicRef58969" href="/z/d/graphic/58969.html" rel="external">picture 7</a>) [<a href="#rid25">25</a>]. Longer hospital stay, respiratory tract complications, and mucosal sequelae are more common in RIME than in EM associated with other triggers [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/5559.html" rel="external">"Erythema multiforme: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) </strong>–<strong> </strong>SJS/TEN is a severe mucocutaneous reaction most commonly triggered by medications in both adults and children and is characterized by extensive necrosis and detachment of the epidermis  (<a class="graphic graphic_picture graphicRef67632" href="/z/d/graphic/67632.html" rel="external">picture 8</a>). Mucosal involvement occurs in approximately 90 percent of cases  (<a class="graphic graphic_picture graphicRef73805" href="/z/d/graphic/73805.html" rel="external">picture 9</a>). Constitutional symptoms, such as fever, are common and may precede the onset of the disease. A history of antecedent exposure to drugs known to cause SJS/TEN is a key diagnostic clue  (<a class="graphic graphic_table graphicRef91163" href="/z/d/graphic/91163.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herpetic gingivostomatitis</strong> – Primary herpetic gingivostomatitis is the most common manifestation of primary HSV infection during childhood [<a href="#rid57">57</a>]. It is characterized by ulcerative lesions of the gingiva and oral mucosa  (<a class="graphic graphic_picture graphicRef122954" href="/z/d/graphic/122954.html" rel="external">picture 10</a>), fever, malaise, anorexia, and lymphadenopathy. Viral culture and polymerase chain reaction (PCR) can confirm the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/6046.html" rel="external">"Herpetic gingivostomatitis in young children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paraneoplastic pemphigus</strong> – Paraneoplastic pemphigus is a rare, autoimmune, blistering disorder linked to an underlying lymphoproliferative disorder that presents with severe, erosive stomatitis and a polymorphous, cutaneous eruption  (<a class="graphic graphic_picture graphicRef59594" href="/z/d/graphic/59594.html" rel="external">picture 11</a>). In children, the most common underlying neoplasm is Castleman disease [<a href="#rid58">58,59</a>]. Direct immunofluorescence and indirect immunofluorescence can confirm the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hand, foot, and mouth disease</strong> – Hand, foot, and mouth disease is caused by multiple coxsackievirus A and B serotypes. Hand, foot, and mouth disease presents with vesicular, cutaneous lesions  (<a class="graphic graphic_picture graphicRef126118" href="/z/d/graphic/126118.html" rel="external">picture 12</a>) and mucosal erosions. The latter are usually well circumscribed and discrete, as opposed to the larger erosions and bullae of RIME  (<a class="graphic graphic_picture graphicRef71314" href="/z/d/graphic/71314.html" rel="external">picture 13</a>). (See  <a class="medical medical_review" href="/z/d/html/96219.html" rel="external">"Hand, foot, and mouth disease and herpangina"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aphthous ulcers </strong>– Aphthae are painful, mucosal ulcerations that can be recurrent in the oral and genital mucosae. In contrast with RIME, aphthous lesions are well demarcated and are typically limited to the nonkeratinized, mucosal surfaces  (<a class="graphic graphic_picture graphicRef122955" href="/z/d/graphic/122955.html" rel="external">picture 14</a>), without involvement of the vermillion lips. (See  <a class="medical medical_review" href="/z/d/html/112654.html" rel="external">"Recurrent aphthous stomatitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multifocal fixed drug eruption</strong> – Multifocal fixed drug eruption can have mucosal involvement but has a distinct cutaneous morphology and histopathology. (See  <a class="medical medical_review" href="/z/d/html/15760.html" rel="external">"Fixed drug eruption"</a>.)</p><p></p><p class="headingAnchor" id="H1341193129"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H990531921"><span class="h2">General considerations</span><span class="headingEndMark"> — </span>There is no evidence-based, established treatment for RIME. Because clinicians may be unable to differentiate RIME from other severe mucocutaneous reactions in the acute care setting, the initial management of RIME is similar as the initial management for patients with suspected Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). It involves immediate in-hospital evaluation for diagnosis confirmation, evaluation of severity, consultation with dermatology and infectious diseases, and initiation of supportive treatment [<a href="#rid60">60</a>]. Based on symptom severity, referral to the most appropriate health care setting should also be considered. (See  <a class="medical medical_review" href="/z/d/html/2092.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae"</a>.)</p><p class="headingAnchor" id="H3316895094"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>Supportive care includes mucosal and skin care, eye care, fluids and nutrition, and pain management. Approximately 4 percent of patients with RIME require intensive care [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/2092.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae", section on 'Supportive care'</a>.)</p><p class="headingAnchor" id="H465328344"><span class="h3">Fluids and nutrition</span><span class="headingEndMark"> — </span>Oral erosions often limit intake of nutrition and fluids; therefore, fluids, electrolytes, and nutrition should be managed actively. Patients who are unable to ingest foods should be offered a nasogastric tube for nutrition. Approximately one-quarter of patients with RIME require nutritional support, and 4 percent require intensive care [<a href="#rid4">4,15</a>].</p><p class="headingAnchor" id="H28762160"><span class="h3">Pain management</span><span class="headingEndMark"> — </span>The amount of analgesia needed depends on the severity of the mucocutaneous lesions. Local management of oral, ocular, urogenital, and cutaneous lesions with ointments and dressings is essential because covered erosions are less painful than those left open to the air. Systemic analgesia may be necessary and should be carefully selected based on the severity of symptoms. (See  <a class="medical medical_review" href="/z/d/html/6254.html" rel="external">"Pain in children: Approach to pain assessment and overview of management principles"</a>.)</p><p class="headingAnchor" id="H3516779576"><span class="h3">Mouth care</span><span class="headingEndMark"> — </span>Oral erosions can be a cause of significant pain and morbidity. Care should be taken to avoid accumulation of a thick crust on the lips. Lips can be soaked with saline-soaked gauze several times a day. Petrolatum or another ointment should be applied liberally many times a day. In patients with severe erosions at the angles of the mouth, petrolatum-soaked gauze can be rolled into small cylinders and placed in the corners of the mouth to prevent scarring.</p><p>Intraoral erosions can be managed with the so-called "magic mouthwash" (a variable combination of topical anesthetics, topical corticosteroids, antibiotics, and antacids) several times a day, as long as the patient is old enough to know how to swish and spit [<a href="#rid61">61</a>]. However, the efficacy of such preparation in reducing pain and discomfort is unproven [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/z/d/html/6046.html" rel="external">"Herpetic gingivostomatitis in young children", section on '"Magic mouthwash" and other topical therapies'</a>.)</p><p>In severe cases, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> swish and spit can be used as a topical treatment. Thrush or herpes simplex virus (HSV) reactivation should be treated if present.</p><p class="headingAnchor" id="H3513240676"><span class="h3">Eye care</span><span class="headingEndMark"> — </span>Ophthalmology should be consulted early when there is ocular involvement, and ocular care should be promptly initiated [<a href="#rid60">60,63,64</a>]. <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">Saline</a> rinses and multiple daily applications of ocular lubricants are indicated for patients with mild conjunctivitis. Amniotic membrane grafting may be required in severe cases with extensive sloughing of the bulbar conjunctiva. (See  <a class="medical medical_review" href="/z/d/html/2092.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae", section on 'Management of ocular involvement'</a>.)</p><p class="headingAnchor" id="H3130961191"><span class="h3">Urogenital lesions</span><span class="headingEndMark"> — </span>Urogenital lesions can be painful and affect normal voiding. Erosions can be treated with liberal application of petrolatum. Topical corticosteroids (eg, <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> 0.1% ointment) can help with pain, erythema, and edema. If pain is mild and voiding is normal, then a Foley catheter is not needed. If normal voiding is not possible, then a Foley catheter may be required, and urology input may be helpful.</p><p class="headingAnchor" id="H2194566411"><span class="h3">Skin care</span><span class="headingEndMark"> — </span>In cases with limited skin involvement, denuded areas should be gently cleaned and covered with petrolatum or another bland emollient and a nonstick dressing. In general, debridement is not necessary. Management in a burn center or intensive care unit may be more appropriate for cases with extensive cutaneous involvement. (See  <a class="medical medical_review" href="/z/d/html/2092.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae", section on 'Wound care'</a>.)</p><p class="headingAnchor" id="H2986500652"><span class="h2">Adjunctive therapies</span></p><p class="headingAnchor" id="H1556361360"><span class="h3">Antibiotics</span><span class="headingEndMark"> — </span>Children with clinical, laboratory, and/or radiographic evidence of community-acquired pneumonia are initially treated empirically with antibiotics that cover <em>M. pneumoniae</em>, <em>C. pneumoniae</em>, and<em> Streptococcus pneumoniae</em> (macrolide, <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, or fluoroquinolone antibiotics), pending results of microbiologic tests. (See  <a class="medical medical_review" href="/z/d/html/6070.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in children", section on 'Empiric therapy'</a> and  <a class="medical medical_review" href="/z/d/html/5957.html" rel="external">"Pneumonia caused by <i>Chlamydia pneumoniae</i> in children", section on 'Empiric therapy for community-acquired pneumonia'</a>.)</p><p>However, whether antibiotic treatment shortens the course of disease remains to be determined [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H4066278969"><span class="h3">Systemic corticosteroids</span><span class="headingEndMark"> — </span>Systemic corticosteroids are frequently used in patients with RIME and extensive mucosal involvement to decrease inflammation and pain. In a review of 202 patients with RIME associated with <em>M. pneumoniae</em>, 35 percent received systemic corticosteroids [<a href="#rid4">4</a>]. Although evidence to support this approach is weak, we suggest a short course (5 to 10 days) of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg/day with no taper in patients with extensive mucosal involvement and severe symptoms.</p><p class="headingAnchor" id="H1652792072"><span class="h3">Other immunomodulatory therapies</span><span class="headingEndMark"> — </span>Other immunomodulatory treatments that have been reported in cases of RIME with severe mucosal involvement include <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid65">65</a>], intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) [<a href="#rid66">66</a>], and anti-tumor necrosis factor (TNF) agents [<a href="#rid67">67,68</a>].</p><p>In a retrospective series of six patients with RIME and evidence of disease progression (age 5 to 13 years), a single dose of subcutaneous <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, 0.6 to 0.8 mg/kg or 50 mg for those who weighed &gt;60 kg, induced clinical improvement in five of six patients within two days of administration [<a href="#rid67">67</a>].</p><p><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> has been reported to be effective in a small case series of pediatric patients with RIME [<a href="#rid65">65</a>]. Patients were treated with cyclosporine 3 to 5 mg/kg/day in two divided doses for 7 to 10 days.</p><p class="headingAnchor" id="H2598280360"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The prognosis of RIME is generally good, with most patients making a full recovery. Recurrence has been reported in at least 8 percent of cases [<a href="#rid4">4,40,41</a>].</p><p>In contrast with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), RIME is associated with a very low mortality rate. In a review of 202 published cases from 1922 to 2013, the mortality rate was 3 percent, and all deaths occurred in the 1940s [<a href="#rid4">4</a>]. <em>C. pneumoniae</em>-induced rash and mucositis has a similarly good prognosis and presentation in school-age children.</p><p>Mucocutaneous sequelae occur in approximately 10 percent of patients and include postinflammatory pigmentary alteration and genital and ocular complications, such as scarring and synechiae [<a href="#rid4">4</a>]. Ocular sequelae, including conjunctival shrinkage, corneal ulcerations, blindness, synechiae, dry eyes, and loss of eyelashes, have been reported in 9 percent of cases [<a href="#rid4">4,64</a>].</p><p>Rare complications include restrictive lung disease or chronic obliterative bronchitis, persistent cutaneous lesions, and B cell lymphopenia.</p><p class="headingAnchor" id="H123657999"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>After recovery from the initial episode, patients should be followed based on their specific sequelae (mouth scarring, pulmonary complications, etc). Patients with cutaneous sequelae (eg, scarring, dyspigmentation) should be reassured about the slow improvement of pigmentary alteration and scarring over time and educated about the importance of sun protection. Patients and families should be counseled on the low, but real, risk of recurrence and instructed to present to care early in the course of disease if recurrence is suspected.</p><p class="headingAnchor" id="H2144543699"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology</strong> – The term "<em>Mycoplasma pneumoniae</em>-induced rash and mucositis" (MIRM) was coined in 2015 to distinguish the mucocutaneous disease associated with <em>Mycoplasma pneumoniae </em>in children and adolescents from the Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) spectrum and erythema multiforme (EM). Based on the subsequent observation that other respiratory infections can trigger a mucocutaneous reaction in children indistinguishable from MIRM, the broader term "reactive infectious mucocutaneous eruption" (RIME) has been proposed. (See <a class="local">'Terminology'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – RIME is characterized by severe mucositis and variable, but generally limited, cutaneous lesions. Most patients experience a prodrome of cough, malaise, and fever for approximately one week prior to the onset of their mucocutaneous eruption. Oral involvement is nearly universal, with hemorrhagic crusting of the lips and erosions on the tongue and buccal mucosa  (<a class="graphic graphic_picture graphicRef126080 graphicRef126081" href="/z/d/graphic/126080.html" rel="external">picture 1A-B</a>). Most patients also have ocular and urogenital involvement  (<a class="graphic graphic_picture graphicRef126082" href="/z/d/graphic/126082.html" rel="external">picture 2</a>). (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Proposed diagnostic criteria for RIME include (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mucocutaneous eruption involving one or more sites with &lt;10 percent body surface area involvement</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Presence of a few vesiculobullous lesions or scattered, atypical, targetoid lesions on skin</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Noncontributory medication history</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of prodromal symptoms (eg, cough, fever, malaise) in the previous 7 to 10 days</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical, radiographic, or laboratory evidence of an infectious trigger (most commonly <em>M. pneumoniae</em>, respiratory viruses, or <em>Chlamydia pneumoniae</em>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial management and supportive care</strong> – The initial management of RIME is similar to the initial management for suspected SJS/TEN and involves immediate in-hospital evaluation for diagnosis confirmation, evaluation of severity, consultation with dermatology and infectious diseases, and initiation of supportive treatment (including mucosal and skin care, eye care, fluids and nutrition, and pain management). (See <a class="local">'Supportive care'</a> above and  <a class="medical medical_review" href="/z/d/html/2092.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae", section on 'Supportive care'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adjunctive therapies</strong>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Empiric antibiotic therapy</strong> – Patients with clinical, laboratory, and/or radiographic evidence of community-acquired pneumonia are initially treated empirically with antibiotics that cover<em> M. pneumoniae</em>, <em>C. pneumoniae</em>, and<em> Streptococcus pneumoniae</em>. (See  <a class="medical medical_review" href="/z/d/html/6070.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in children", section on 'Empiric therapy'</a> and  <a class="medical medical_review" href="/z/d/html/5957.html" rel="external">"Pneumonia caused by <i>Chlamydia pneumoniae</i> in children", section on 'Empiric therapy for community-acquired pneumonia'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Immunomodulatory therapies </strong>– For patients with extensive mucosal involvement or high burden of symptoms, we suggest a short course of systemic corticosteroids rather than intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). A reasonable regimen is <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg/day for 5 to 10 days. <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> (at a dose of 3 to 5 mg/kg/day for 7 to 10 days) or a single dose of <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> may be an alternative to systemic corticosteroids. (See <a class="local">'Systemic corticosteroids'</a> above and <a class="local">'Other immunomodulatory therapies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ramien ML, Bahubeshi A, Lara-Corrales I, et al. Blistering severe cutaneous adverse reactions in children: proposal for paediatric-focused clinical criteria. Br J Dermatol 2021; 185:447.</a></li><li><a class="nounderline abstract_t">Lofgren D, Lenkeit C. Mycoplasma Pneumoniae-Induced Rash and Mucositis: A Systematic Review of the Literature. Spartan Med Res J 2021; 6:25284.</a></li><li><a class="nounderline abstract_t">Pan CX, Hussain SH. Recurrent reactive infectious mucocutaneous eruption: A retrospective cohort study. J Am Acad Dermatol 2023; 89:361.</a></li><li><a class="nounderline abstract_t">Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol 2015; 72:239.</a></li><li><a class="nounderline abstract_t">Tay YK, Huff JC, Weston WL. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol 1996; 35:757.</a></li><li><a class="nounderline abstract_t">Cannell H, Churcher GM, Milton-Thompson GJ. Stevens-Johnson syndrome associated with Mycoplasma pneumoniae infection. Br J Dermatol 1969; 81:196.</a></li><li><a class="nounderline abstract_t">Moreau JF, Watson RS, Hartman ME, et al. Epidemiology of ophthalmologic disease associated with erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis in hospitalized children in the United States. Pediatr Dermatol 2014; 31:163.</a></li><li><a class="nounderline abstract_t">Ravin KA, Rappaport LD, Zuckerbraun NS, et al. Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome: a case series. Pediatrics 2007; 119:e1002.</a></li><li><a class="nounderline abstract_t">Meyer Sauteur PM, Gansser-Kälin U, Lautenschlager S, Goetschel P. Fuchs syndrome associated with Mycoplasma pneumoniae (Stevens-Johnson syndrome without skin lesions). Pediatr Dermatol 2011; 28:474.</a></li><li><a class="nounderline abstract_t">Kheiri B, Alhesan NA, Madala S, et al. Mycoplasma pneumoniae-associated Fuchs syndrome. Clin Case Rep 2018; 6:434.</a></li><li><a class="nounderline abstract_t">Fournier S, Bastuji-Garin S, Mentec H, et al. Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. Eur J Clin Microbiol Infect Dis 1995; 14:558.</a></li><li><a class="nounderline abstract_t">Grosber M, Alexandre M, Poszepczynska-Guigné E, et al. Recurrent erythema multiforme in association with recurrent Mycoplasma pneumoniae infections. J Am Acad Dermatol 2007; 56:S118.</a></li><li><a class="nounderline abstract_t">Schalock PC, Dinulos JG. Mycoplasma pneumoniae-induced Stevens-Johnson syndrome without skin lesions: fact or fiction? J Am Acad Dermatol 2005; 52:312.</a></li><li><a class="nounderline abstract_t">Schalock PC, Thyssen JP, Dinulos JG. Mycoplasma pneumoniae-associated mucositis: by any other name is not so sweet. Pediatr Dermatol 2012; 29:392.</a></li><li><a class="nounderline abstract_t">Vujic I, Shroff A, Grzelka M, et al. Mycoplasma pneumoniae-associated mucositis--case report and systematic review of literature. J Eur Acad Dermatol Venereol 2015; 29:595.</a></li><li><a class="nounderline abstract_t">Ramien ML. Reactive infectious mucocutaneous eruption: Mycoplasma pneumoniae-induced rash and mucositis and other parainfectious eruptions. Clin Exp Dermatol 2021; 46:420.</a></li><li><a class="nounderline abstract_t">Ramien ML, Bruckner AL. Mucocutaneous Eruptions in Acutely Ill Pediatric Patients-Think of Mycoplasma pneumoniae (and Other Infections) First. JAMA Dermatol 2020; 156:124.</a></li><li><a class="nounderline abstract_t">Mayor-Ibarguren A, Feito-Rodriguez M, González-Ramos J, et al. Mucositis Secondary to Chlamydia pneumoniae Infection: Expanding the Mycoplasma pneumoniae-Induced Rash and Mucositis Concept. Pediatr Dermatol 2017; 34:465.</a></li><li><a class="nounderline abstract_t">Bowe S, O'Connor C, Gleeson C, Murphy M. Reactive infectious mucocutaneous eruption in children diagnosed with COVID-19. Pediatr Dermatol 2021; 38:1385.</a></li><li><a class="nounderline abstract_t">Prindaville B, Newell BD, Nopper AJ, Horii KA. Mycoplasma pneumonia--associated mucocutaneous disease in children: dilemmas in classification. Pediatr Dermatol 2014; 31:670.</a></li><li><a class="nounderline abstract_t">Zão I, Ribeiro F, Rocha V, et al. Mycoplasma pneumoniae-associated Mucositis: A Recently Described Entity. Eur J Case Rep Intern Med 2018; 5:000977.</a></li><li><a class="nounderline abstract_t">Li T, Lee N. Mycoplasma pneumoniae-Associated Mucositis. N Engl J Med 2018; 379:1262.</a></li><li><a class="nounderline abstract_t">Gandelman JS, Kim EY, Grzegorczyk AM, et al. Mycoplasma pneumoniae-Induced Rash and Mucositis in a Previously Healthy Man: A Case Report and Brief Review of the Literature. Open Forum Infect Dis 2020; 7:ofaa437.</a></li><li><a class="nounderline abstract_t">Smilga AS, Fournier S, Veillette H, et al. A rare case of Mycoplasma-induced rash and mucositis in a 44-year-old female patient. JAAD Case Rep 2020; 6:1333.</a></li><li><a class="nounderline abstract_t">Amode R, Ingen-Housz-Oro S, Ortonne N, et al. Clinical and histologic features of Mycoplasma pneumoniae-related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes. J Am Acad Dermatol 2018; 79:110.</a></li><li><a class="nounderline abstract_t">Watkins LKF, Olson D, Diaz MH, et al. Epidemiology and Molecular Characteristics of Mycoplasma pneumoniae During an Outbreak of M. pneumoniae-associated Stevens-Johnson Syndrome. Pediatr Infect Dis J 2017; 36:564.</a></li><li><a class="nounderline abstract_t">Olson D, Watkins LK, Demirjian A, et al. Outbreak of Mycoplasma pneumoniae-Associated Stevens-Johnson Syndrome. Pediatrics 2015; 136:e386.</a></li><li><a class="nounderline abstract_t">Gordon O, Oster Y, Michael-Gayego A, et al. The Clinical Presentation of Pediatric Mycoplasma pneumoniae Infections-A Single Center Cohort. Pediatr Infect Dis J 2019; 38:698.</a></li><li><a class="nounderline abstract_t">Meyer Sauteur PM, Theiler M, Buettcher M, et al. Frequency and Clinical Presentation of Mucocutaneous Disease Due to Mycoplasma pneumoniae Infection in Children With Community-Acquired Pneumonia. JAMA Dermatol 2020; 156:144.</a></li><li><a class="nounderline abstract_t">Umapathi KK, Tuli J, Menon S. Chlamydia pneumonia - induced mucositis. Pediatr Neonatol 2019; 60:697.</a></li><li><a class="nounderline abstract_t">Goyal A, Hook K. Two pediatric cases of influenza B-induced rash and mucositis: Stevens-Johnson syndrome or expansion of the Mycoplasma pneumoniae-induced rash with mucositis (MIRM) spectrum? Pediatr Dermatol 2019; 36:929.</a></li><li><a class="nounderline abstract_t">Tsai TY, Chao YC, Lai YH, Huang YC. Coxsackievirus B5-induced severe mucocutaneous reaction mimicking drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Indian J Dermatol Venereol Leprol 2019; 85:416.</a></li><li><a class="nounderline abstract_t">Gámez-González LB, Peña-Varela C, Ramírez-López JM, Yamazaki-Nakashimada MA. Adenoviral-induced rash and mucositis: Expanding the spectrum of reactive infectious mucocutaneous eruption. Pediatr Dermatol 2021; 38:306.</a></li><li><a class="nounderline abstract_t">Song A, Nicholson C, Maguiness S. Recurrent reactive infectious mucocutaneous eruption (RIME) in two adolescents triggered by several distinct pathogens including SARS-CoV-2 and influenza A. Pediatr Dermatol 2021; 38:1222.</a></li><li><a class="nounderline abstract_t">Mota B, Martins A, Pereira-Nunes J, et al. A Severe Case of Post-COVID-19 Reactive Infectious Mucocutaneous Eruption in a Pediatric Patient. Pediatr Infect Dis J 2023; 42:e54.</a></li><li><a class="nounderline abstract_t">Wu D, Lee EY, Lifton J, et al. Severe recurrence of reactive infectious mucocutaneous eruption with extensive ocular involvement in an adult due to SARS-CoV-2. JAAD Case Rep 2023; 36:1.</a></li><li><a class="nounderline abstract_t">Campagna C, Tassinari D, Neri I, Bernardi F. Mycoplasma pneumoniae-induced recurrent Stevens-Johnson syndrome in children: a case report. Pediatr Dermatol 2013; 30:624.</a></li><li><a class="nounderline abstract_t">Smith CC, Umapathy D. Erythema multiforme in a mother and daughter after M. pneumoniae infection; a coincidence? Br J Dermatol 1987; 117:533.</a></li><li><a class="nounderline abstract_t">Song H, Huang JT, Tan JK. Mycoplasma-Induced Rash and Mucositis in a Father and Son: A Case Report. Pediatr Infect Dis J 2018; 37:e205.</a></li><li><a class="nounderline abstract_t">Olson D, Abbott J, Lin C, et al. Characterization of Children With Recurrent Episodes of Stevens Johnson Syndrome. J Pediatric Infect Dis Soc 2017; 6:e140.</a></li><li><a class="nounderline abstract_t">Liakos W, Xu A, Finelt N. Clinical features of recurrent Mycoplasma pneumoniae-induced rash and mucositis. Pediatr Dermatol 2021; 38:154.</a></li><li><a class="nounderline abstract_t">Fernald GW. Immunological interactions between host cells and mycoplasmas: an introduction. Rev Infect Dis 1982; 4 Suppl:S201.</a></li><li><a class="nounderline abstract_t">Simecka JW, Ross SE, Cassell GH, Davis JK. Interactions of mycoplasmas with B cells: antibody production and nonspecific effects. Clin Infect Dis 1993; 17 Suppl 1:S176.</a></li><li><a class="nounderline abstract_t">Meseguer MA, de Rafael L, Vidal ML. Stevens-Johnson syndrome with isolation of Mycoplasma pneumoniae from skin lesions. Eur J Clin Microbiol 1986; 5:167.</a></li><li><a class="nounderline abstract_t">Lyell A, Gordon AM, Dick HM, Sommerville RG. Mycoplasmas and erythema multiforme. Lancet 1967; 2:1116.</a></li><li><a class="nounderline abstract_t">Stutman HR. Stevens-Johnson syndrome and Mycoplasma pneumoniae: evidence for cutaneous infection. J Pediatr 1987; 111:845.</a></li><li><a class="nounderline abstract_t">Narita M. Classification of Extrapulmonary Manifestations Due to Mycoplasma pneumoniae Infection on the Basis of Possible Pathogenesis. Front Microbiol 2016; 7:23.</a></li><li><a class="nounderline abstract_t">Shah PR, Williams AM, Pihlblad MS, Nischal KK. Ophthalmic Manifestations of Mycoplasma-Induced Rash and Mucositis. Cornea 2019; 38:1305.</a></li><li><a class="nounderline abstract_t">Norton SA. Diagnosing Mycoplasma pneumoniae-induced rash and mucositis (MIRM) in the emergency room. J Am Acad Dermatol 2015; 73:e67.</a></li><li><a class="nounderline abstract_t">Poddighe D, Bruni P. Mycoplasma pneumoniae-induced rash and mucositis (MIRM): an unusual mild skin rash associated with severe mucosal involvement. BMJ Case Rep 2017; 2017.</a></li><li><a class="nounderline abstract_t">Chao K, Balin S, Sorenson E, Worswick S. Mycoplasma-induced pustulosis with perifollicular involvement. Dermatol Online J 2018; 24.</a></li><li><a class="nounderline abstract_t">Wetter DA, Davis MD. Recurrent erythema multiforme: clinical characteristics, etiologic associations, and treatment in a series of 48 patients at Mayo Clinic, 2000 to 2007. J Am Acad Dermatol 2010; 62:45.</a></li><li><a class="nounderline abstract_t">Rzany B, Hering O, Mockenhaupt M, et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996; 135:6.</a></li><li><a class="nounderline abstract_t">Lee WJ, Huang EY, Tsai CM, et al. Role of Serum Mycoplasma pneumoniae IgA, IgM, and IgG in the Diagnosis of Mycoplasma pneumoniae-Related Pneumonia in School-Age Children and Adolescents. Clin Vaccine Immunol 2017; 24.</a></li><li><a class="nounderline abstract_t">Leber AL, Everhart K, Daly JA, et al. Multicenter Evaluation of BioFire FilmArray Respiratory Panel 2 for Detection of Viruses and Bacteria in Nasopharyngeal Swab Samples. J Clin Microbiol 2018; 56.</a></li><li><a class="nounderline abstract_t">Sanfilippo E, Habeshian K, Cotton CH, Kirkorian AY. Severe reactive infectious mucocutaneous eruption mimicking drug-induced epidermal necrolysis triggered by norovirus. Pediatr Dermatol 2023.</a></li><li class="breakAll">Aslanova M, Zito PM. Herpetic gingivostomatitis. In: StatPearls, StatPearls Publishing, 2019.</li><li><a class="nounderline abstract_t">Mimouni D, Anhalt GJ, Lazarova Z, et al. Paraneoplastic pemphigus in children and adolescents. Br J Dermatol 2002; 147:725.</a></li><li><a class="nounderline abstract_t">Ohzono A, Sogame R, Li X, et al. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol 2015; 173:1447.</a></li><li><a class="nounderline abstract_t">McPherson T, Exton LS, Biswas S, et al. British Association of Dermatologists' guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018. Br J Dermatol 2019; 181:37.</a></li><li><a class="nounderline abstract_t">Kravitz ND, Crutchfield WE, Miller S, Gill J. Magic mouthwash demystified. J Clin Orthod 2020; 54:462.</a></li><li><a class="nounderline abstract_t">Hopper SM, McCarthy M, Tancharoen C, et al. Topical lidocaine to improve oral intake in children with painful infectious mouth ulcers: a blinded, randomized, placebo-controlled trial. Ann Emerg Med 2014; 63:292.</a></li><li><a class="nounderline abstract_t">Kohanim S, Palioura S, Saeed HN, et al. Acute and Chronic Ophthalmic Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - A Comprehensive Review and Guide to Therapy. II. Ophthalmic Disease. Ocul Surf 2016; 14:168.</a></li><li><a class="nounderline abstract_t">Gise R, Elhusseiny AM, Scelfo C, Mantagos IS. Mycoplasma Pneumoniae-Induced Rash and Mucositis: A Longitudinal Perspective and Proposed Management Criteria. Am J Ophthalmol 2020; 219:351.</a></li><li><a class="nounderline abstract_t">Li HO, Colantonio S, Ramien ML. Treatment of Mycoplasma pneumoniae-Induced Rash and Mucositis With Cyclosporine [Formula: see text]. J Cutan Med Surg 2019; 23:608.</a></li><li><a class="nounderline abstract_t">Santos RP, Silva M, Vieira AP, Brito C. Mycoplasma pneumoniae-induced rash and mucositis: a recently described entity. BMJ Case Rep 2017; 2017.</a></li><li><a class="nounderline abstract_t">Miller MM, Kamath S, Hughes M, et al. Evaluation of Etanercept for Treatment of Reactive Infectious Mucocutaneous Eruption. JAMA Dermatol 2021; 157:230.</a></li><li><a class="nounderline abstract_t">Tonkin R, Ladha M, Johnson N, et al. Reactive infectious mucocutaneous eruption - repeat etanercept after intravenous immunoglobulin: A case report. SAGE Open Med Case Rep 2022; 10:2050313X221117887.</a></li></ol></div><div id="topicVersionRevision">Topic 120346 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33730370" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Blistering severe cutaneous adverse reactions in children: proposal for paediatric-focused clinical criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34532621" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mycoplasma Pneumoniae-Induced Rash and Mucositis: A Systematic Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36997070" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Recurrent reactive infectious mucocutaneous eruption: A retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25592340" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8912572" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5775068" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Stevens-Johnson syndrome associated with Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23679157" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Epidemiology of ophthalmologic disease associated with erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis in hospitalized children in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17353300" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20678095" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fuchs syndrome associated with Mycoplasma pneumoniae (Stevens-Johnson syndrome without skin lesions).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29445492" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mycoplasma pneumoniae-associated Fuchs syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7588837" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17434037" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Recurrent erythema multiforme in association with recurrent Mycoplasma pneumoniae infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15692479" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mycoplasma pneumoniae-induced Stevens-Johnson syndrome without skin lesions: fact or fiction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22594340" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mycoplasma pneumoniae-associated mucositis: by any other name is not so sweet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24665876" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mycoplasma pneumoniae-associated mucositis--case report and systematic review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32918499" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Reactive infectious mucocutaneous eruption: Mycoplasma pneumoniae-induced rash and mucositis and other parainfectious eruptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31851301" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mucocutaneous Eruptions in Acutely Ill Pediatric Patients-Think of Mycoplasma pneumoniae (and Other Infections) First.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28568680" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mucositis Secondary to Chlamydia pneumoniae Infection: Expanding the Mycoplasma pneumoniae-Induced Rash and Mucositis Concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34542915" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Reactive infectious mucocutaneous eruption in children diagnosed with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25424207" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mycoplasma pneumonia--associated mucocutaneous disease in children: dilemmas in classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30755992" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mycoplasma pneumoniae-associated Mucositis: A Recently Described Entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30257151" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mycoplasma pneumoniae-Associated Mucositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33094121" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mycoplasma pneumoniae-Induced Rash and Mucositis in a Previously Healthy Man: A Case Report and Brief Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32989421" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A rare case of Mycoplasma-induced rash and mucositis in a 44-year-old female patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29559400" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical and histologic features of Mycoplasma pneumoniae-related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28060039" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Epidemiology and Molecular Characteristics of Mycoplasma pneumoniae During an Outbreak of M. pneumoniae-associated Stevens-Johnson Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26216320" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Outbreak of Mycoplasma pneumoniae-Associated Stevens-Johnson Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30985519" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The Clinical Presentation of Pediatric Mycoplasma pneumoniae Infections-A Single Center Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31851288" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Frequency and Clinical Presentation of Mucocutaneous Disease Due to Mycoplasma pneumoniae Infection in Children With Community-Acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31239206" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Chlamydia pneumonia - induced mucositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31576583" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Two pediatric cases of influenza B-induced rash and mucositis: Stevens-Johnson syndrome or expansion of the Mycoplasma pneumoniae-induced rash with mucositis (MIRM) spectrum?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31062724" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Coxsackievirus B5-induced severe mucocutaneous reaction mimicking drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33063905" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Adenoviral-induced rash and mucositis: Expanding the spectrum of reactive infectious mucocutaneous eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34515364" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Recurrent reactive infectious mucocutaneous eruption (RIME) in two adolescents triggered by several distinct pathogens including SARS-CoV-2 and influenza A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36638409" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A Severe Case of Post-COVID-19 Reactive Infectious Mucocutaneous Eruption in a Pediatric Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36819988" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Severe recurrence of reactive infectious mucocutaneous eruption with extensive ocular involvement in an adult due to SARS-CoV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24016288" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Mycoplasma pneumoniae-induced recurrent Stevens-Johnson syndrome in children: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3676100" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Erythema multiforme in a mother and daughter after M. pneumoniae infection; a coincidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29278609" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mycoplasma-Induced Rash and Mucositis in a Father and Son: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28339562" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Characterization of Children With Recurrent Episodes of Stevens Johnson Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33247484" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical features of recurrent Mycoplasma pneumoniae-induced rash and mucositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6750755" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Immunological interactions between host cells and mycoplasmas: an introduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399911" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Interactions of mycoplasmas with B cells: antibody production and nonspecific effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3087748" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Stevens-Johnson syndrome with isolation of Mycoplasma pneumoniae from skin lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4168557" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mycoplasmas and erythema multiforme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3119808" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Stevens-Johnson syndrome and Mycoplasma pneumoniae: evidence for cutaneous infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26858701" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Classification of Extrapulmonary Manifestations Due to Mycoplasma pneumoniae Infection on the Basis of Possible Pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31246679" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Ophthalmic Manifestations of Mycoplasma-Induced Rash and Mucositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26184002" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Diagnosing Mycoplasma pneumoniae-induced rash and mucositis (MIRM) in the emergency room.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28551607" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Mycoplasma pneumoniae-induced rash and mucositis (MIRM): an unusual mild skin rash associated with severe mucosal involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29634880" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Mycoplasma-induced pustulosis with perifollicular involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19665257" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Recurrent erythema multiforme: clinical characteristics, etiologic associations, and treatment in a series of 48 patients at Mayo Clinic, 2000 to 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8776350" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27760779" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Role of Serum Mycoplasma pneumoniae IgA, IgM, and IgG in the Diagnosis of Mycoplasma pneumoniae-Related Pneumonia in School-Age Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29593057" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Multicenter Evaluation of BioFire FilmArray Respiratory Panel 2 for Detection of Viruses and Bacteria in Nasopharyngeal Swab Samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37317663" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Severe reactive infectious mucocutaneous eruption mimicking drug-induced epidermal necrolysis triggered by norovirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37317663" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Severe reactive infectious mucocutaneous eruption mimicking drug-induced epidermal necrolysis triggered by norovirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12366419" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Paraneoplastic pemphigus in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26358412" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical and immunological findings in 104 cases of paraneoplastic pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30829411" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : British Association of Dermatologists' guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32966265" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Magic mouthwash demystified.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24210368" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Topical lidocaine to improve oral intake in children with painful infectious mouth ulcers: a blinded, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26882981" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Acute and Chronic Ophthalmic Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - A Comprehensive Review and Guide to Therapy. II. Ophthalmic Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32574770" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Mycoplasma Pneumoniae-Induced Rash and Mucositis: A Longitudinal Perspective and Proposed Management Criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31502864" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Treatment of Mycoplasma pneumoniae-Induced Rash and Mucositis With Cyclosporine [Formula: see text].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28830900" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Mycoplasma pneumoniae-induced rash and mucositis: a recently described entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33439235" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Evaluation of Etanercept for Treatment of Reactive Infectious Mucocutaneous Eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36003890" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Reactive infectious mucocutaneous eruption - repeat etanercept after intravenous immunoglobulin: A case report.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
